Biopharma alliances succeed or fail for reasons that are often misunderstood. Many leaders still assume that partner selection, strategic fit, or agreement quality determine performance. These factors matter, but they do not explain why alliances with similar science, investment, and structures often produce quite different outcomes. Our work demonstrates that alliance success is determined by execution effectiveness—specifically decision clarity and velocity, governance functionality, escalation effectiveness, leadership engagement, enterprise integration, and cross-organizational alignment.

Execution effectiveness—the ability to turn strategy into coordinated action across organizations—with speed, clarity, and alignment drives alliance performance. It is both the most obvious and the most overlooked determinant of value realization. Some alliances move quickly and stay aligned. Others slow down, get stuck, or quietly lose value. That divergence is not random. It reflects how well the organizations execute once the work begins.

Why Execution Effectiveness Matters More Than Strategy or Structure

The Alliance Execution Effectiveness Model™ reframes how value is created in alliances. It shows (See Figure 1) that performance follows a clear causal chain. Strategy and agreements define potential value. Structural capability enables execution. Operating discipline determines whether execution works in practice. Execution effectiveness determines whether potential value becomes realized value.

Figure 1 – Alliance Execution Effectiveness Model TM

This model resolves a long‑standing paradox in biopharma: alliances with strong strategic rationale and well‑constructed agreements often underperform because execution breaks down, while alliances with imperfect agreements succeed when execution is strong.

Alliance value realization can be expressed conceptually as Value Realization is a function of Value Potential multiplied by Execution Effectiveness. Alliance professionals therefore carry the responsibility to build and sustain the operating discipline that enables effective joint execution.

The Industry Has Shifted—Execution Must Shift with It

The model reflects a structural change in biopharma. Companies no longer operate as self‑contained value systems. They function as nodes in a distributed network of interdependent organizations collectively responsible for value creation.

This shift changes what drives performance. In a vertically integrated model, execution depended on internal alignment and management capability. In a partner‑dependent model, execution depends on how well multiple independent organizations operate as a coherent execution system.

Contractual rigor and governance structure still matter, but they no longer determine performance. Joint execution systems do. This shift necessitates the transformation of alliance management from a strategically savvy, essential orchestration function to a core enterprise execution capability.

Alliance professionals still manage governance, solve problems, deliver on obligations, engage stakeholders, and facilitate relationships. But these activities are not sufficient. They now design and lead the operating practices and discipline that determine whether value is realized or eroded.

Execution Determines Value Realization

The Alliance Execution Effectiveness Model™ rests on a simple principle: execution determines value realization. The model is multi-layered, with each layer informing the next.

Strategy defines the rationale for the alliance. Agreements define rights, incentives, and governance. Structural capability provides management systems to support the alliance. But none of these create value on their own. Operating discipline determines whether execution works day to day. Execution effectiveness determines whether potential value becomes realized value.

Alliance Management Is an Execution Discipline

The model clarifies the role of alliance professionals. They shape the operating discipline that drives alliance performance. Their responsibilities fall into three core areas:

• Engineer value realization by translating strategy and agreements into effective operating discipline.
• Reduce alliance risk by implementing consistent alliance processes and procedures.
• Mobilize the enterprise by educating leaders, governance members, and alliance teams about their roles and key alliance responsibilities.

When execution is strong, alliances deliver intended value—unless the science fails. When execution weakens, value erodes regardless of strategy or agreement quality. Alliance management is therefore fundamentally an execution discipline. In a partner‑dependent biopharma model, execution effectiveness is a strategic capability, the core responsibility of alliance professionals, and a primary determinant of enterprise performance.